After signing up, you'll start to receive regular news updates from us.
BioFocus DPI Launches GPCR SARfari
Complete the form below to unlock access to ALL audio articles.
BioFocus DPI is launching a new version of the GPCR SARfari discovery tool at the American Chemical Society meeting this week in San Diego (USA). Following the success of the Kinase SARfari launched in June, GPCR SARfari now also combines chemical and biological GPCR data from both internal and public sources into a single, dynamic system.
GPCRs play a key role in many human diseases, making them of strategic importance to the pharmaceutical industry. GPCR SARfari enables the user to design compounds and focused libraries against specific GPCRs and optimize compound discovery through exploration of structure-activity relationships. The system comes pre-populated with:
• Full complement of 297 human Class 1 non-olfactory GPCRs
• Comprehensive names, synonyms and targets for FDA approved drugs
• More than 77,000 bioactive GPCR-focused compounds and more than 300,000 experimental end points abstracted from the literature
• Six different binding site views for all 297 GPCRs, enabling comparison and clustering based on binding site properties
• Pre-calculated site profiles for each GPCR using almost 500 physicochemical descriptors
Dr. John Overington, Senior Director of Discovery Informatics at BioFocus DPI, said “The key advantage of this latest release of GPCR SARfari is its ability to integrate biological and chemical data from public and proprietary sources. The result is a more powerful, single-sweep, data mining resource that provides a unique insight on GPCR drug discovery.”
Dr. Overington will present this new GPCR drug discovery tool at this week’s ACS meeting in San Diego. In the talk entitled “Large-scale databases applied to chemogenomics” he will discuss the value of integrating knowledge resources to facilitate effective drug discovery.
